IBDEI2T7 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44808,2)
 ;;=^5002533
 ;;^UTILITY(U,$J,358.3,44809,0)
 ;;=E08.621^^170^2236^24
 ;;^UTILITY(U,$J,358.3,44809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44809,1,3,0)
 ;;=3^Diabetes d/t Underlying Conditions w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,44809,1,4,0)
 ;;=4^E08.621
 ;;^UTILITY(U,$J,358.3,44809,2)
 ;;=^5002534
 ;;^UTILITY(U,$J,358.3,44810,0)
 ;;=T81.33XA^^170^2236^27
 ;;^UTILITY(U,$J,358.3,44810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44810,1,3,0)
 ;;=3^Disruption Traumatic Inj/Wound Repair,Init Encntr
 ;;^UTILITY(U,$J,358.3,44810,1,4,0)
 ;;=4^T81.33XA
 ;;^UTILITY(U,$J,358.3,44810,2)
 ;;=^5054476
 ;;^UTILITY(U,$J,358.3,44811,0)
 ;;=L60.3^^170^2236^30
 ;;^UTILITY(U,$J,358.3,44811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44811,1,3,0)
 ;;=3^Dystrophic Nails
 ;;^UTILITY(U,$J,358.3,44811,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,44811,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,44812,0)
 ;;=M71.30^^170^2236^25
 ;;^UTILITY(U,$J,358.3,44812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44812,1,3,0)
 ;;=3^Digital Mucous Cyst
 ;;^UTILITY(U,$J,358.3,44812,1,4,0)
 ;;=4^M71.30
 ;;^UTILITY(U,$J,358.3,44812,2)
 ;;=^5013149
 ;;^UTILITY(U,$J,358.3,44813,0)
 ;;=L30.4^^170^2237^10
 ;;^UTILITY(U,$J,358.3,44813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44813,1,3,0)
 ;;=3^Erythema Intertrigo
 ;;^UTILITY(U,$J,358.3,44813,1,4,0)
 ;;=4^L30.4
 ;;^UTILITY(U,$J,358.3,44813,2)
 ;;=^5009157
 ;;^UTILITY(U,$J,358.3,44814,0)
 ;;=R60.0^^170^2237^6
 ;;^UTILITY(U,$J,358.3,44814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44814,1,3,0)
 ;;=3^Edema,Localized
 ;;^UTILITY(U,$J,358.3,44814,1,4,0)
 ;;=4^R60.0
 ;;^UTILITY(U,$J,358.3,44814,2)
 ;;=^5019532
 ;;^UTILITY(U,$J,358.3,44815,0)
 ;;=L53.0^^170^2237^14
 ;;^UTILITY(U,$J,358.3,44815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44815,1,3,0)
 ;;=3^Erythema Toxic
 ;;^UTILITY(U,$J,358.3,44815,1,4,0)
 ;;=4^L53.0
 ;;^UTILITY(U,$J,358.3,44815,2)
 ;;=^5009207
 ;;^UTILITY(U,$J,358.3,44816,0)
 ;;=L53.1^^170^2237^9
 ;;^UTILITY(U,$J,358.3,44816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44816,1,3,0)
 ;;=3^Erythema Annulare Centrifugum
 ;;^UTILITY(U,$J,358.3,44816,1,4,0)
 ;;=4^L53.1
 ;;^UTILITY(U,$J,358.3,44816,2)
 ;;=^5009208
 ;;^UTILITY(U,$J,358.3,44817,0)
 ;;=L51.9^^170^2237^12
 ;;^UTILITY(U,$J,358.3,44817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44817,1,3,0)
 ;;=3^Erythema Multiforme,Unspec
 ;;^UTILITY(U,$J,358.3,44817,1,4,0)
 ;;=4^L51.9
 ;;^UTILITY(U,$J,358.3,44817,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,44818,0)
 ;;=L12.35^^170^2237^8
 ;;^UTILITY(U,$J,358.3,44818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44818,1,3,0)
 ;;=3^Epidermolysis Bullosa,Acquired
 ;;^UTILITY(U,$J,358.3,44818,1,4,0)
 ;;=4^L12.35
 ;;^UTILITY(U,$J,358.3,44818,2)
 ;;=^5009100
 ;;^UTILITY(U,$J,358.3,44819,0)
 ;;=L52.^^170^2237^13
 ;;^UTILITY(U,$J,358.3,44819,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44819,1,3,0)
 ;;=3^Erythema Nodosum
 ;;^UTILITY(U,$J,358.3,44819,1,4,0)
 ;;=4^L52.
 ;;^UTILITY(U,$J,358.3,44819,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,44820,0)
 ;;=L49.0^^170^2237^26
 ;;^UTILITY(U,$J,358.3,44820,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44820,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ < 10% Body Surface
 ;;^UTILITY(U,$J,358.3,44820,1,4,0)
 ;;=4^L49.0
 ;;^UTILITY(U,$J,358.3,44820,2)
 ;;=^5009190
 ;;^UTILITY(U,$J,358.3,44821,0)
 ;;=L49.1^^170^2237^17
 ;;^UTILITY(U,$J,358.3,44821,1,0)
 ;;=^358.31IA^4^2
